The role of intravenous immunoglobulin in the treatment of chronic heart failure

International Journal of Cardiology

Volumn 112, Issue 1, 2006, Pages 40-45

  Aukrust, Pål ^a,b   Yndestad, Arne ^a   Ueland, Thor ^a,b   Kristian Damås, Jan ^a   S Frøland, Stig ^a,b   Gullestad, Lars ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chronic heart failure; Cytokine network; Intravenous immunoglobulin

Indexed keywords

AUTOANTIBODY; COMPLEMENT INHIBITOR; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DERMATOMYOSITIS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

AUTOANTIBODIES; CARDIOMYOPATHY, DILATED; CHRONIC DISEASE; COMPLEMENT ACTIVATION; CYTOKINES; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 33747341095     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.05.015     Document Type: Article

References (59)

1. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
2. Aukrust P., Gullestad L., Ueland T., Damås J.K., and Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 37 (2005) 74-85
3. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
4. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83 (1999) 376-382
5. Damås J.K., Gullestad L., Aass H., et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 38 (2001) 187-193
6. Yndestad A., Damås J.K., Eiken H.G., et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 54 (2002) 175-182
7. Yndestad A., Holm A.M., Müller F., et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 60 (2003) 141-146
8. Mann D.L., McMurray J.J.V., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
9. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
10. Anker S.D., and Coats A.J.S. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86 (2002) 123-130
11. Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors. J Rheumatol Suppl 74 (2005) 3-7
12. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
13. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol 274 (1998) R577-R595
14. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
15. Jolles S., Sewell W.A., and Misbah S.A. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142 (2005) 1-11
16. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291 (2004) 2367-2375
17. Bozkurt B., Villaneuva F.S., Holubkov R., et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34 (1999) 177-180
18. McNamara D.M., Rosenblum W.D., Janosko K.M., et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 95 (1997) 2476-2478
19. Gullestad L., Aass H., Fjeld J.G., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 (2001) 220-225
20. McNamara D.M., Holubkov R., Starling R.C., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103 (2001) 2254-2259
21. Gullestad L., and Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 95 (2005) 17C-23C [discussion 38C-40C]
22. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 100 (1997) 151-157
23. Takei S., Arora Y.K., and Walker S.M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 91 (1993) 602-607
24. Jin F., and Balthasar J.P. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol 66 (2005) 403-410
25. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
26. Shioji K., Kishimoto C., and Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res 89 (2001) 540-546
27. Vassilev T.L., Kazatchkine M.D., Van Huyen J.P., et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93 (1999) 3624-3631
28. Gill V., Doig C., Knight D., Love E., and Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 112 (2005) 2031-2039
29. Arredondo J., Chernyavsky A.I., Karaouni A., and Grando S.A. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 167 (2005) 1531-1544
30. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
31. Yaniv G., Shilkrut M., Lotan R., et al. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Cardiovasc Res 54 (2002) 611-623
32. Eriksson U., Ricci R., Hunziker L., et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9 (2003) 1484-1490
33. Bayry J., Lacroix-Desmazes S., Carbonneil C., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2003) 758-765
34. Mobini R., Maschke H., and Waagstein F. New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy. Autoimmun Rev 3 (2004) 277-284
35. Lemieux R., Bazin R., and Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 42 (2005) 839-848
36. Akilesh S., Petkova S., Sproule T.J., et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 113 (2004) 1328-1333
37. Li N., Zhao M., Hilario-Vargas J., et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115 (2005) 3440-3450
38. Larsson L., Mobini R., Aukrust P., et al. Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody. Autoimmunity 37 (2004) 489-493
39. Felix S.B., Staudt A., Landsberger M., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 39 (2002) 646-652
40. Basta M., Van Goor F., Luccioli S., et al. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9 (2003) 431-438
41. Aukrust P., Gullestad L., Lappegård K.T., et al. Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation 104 (2001) 1494-1500
42. Basta M., Fries L.F., and Frank M.M. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77 (1991) 376-380
43. Mollnes T.E., Andreassen I.H., Hogasen K., Hack C.E., and Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol 34 (1997) 719-729
44. Mollnes T.E., Hogasen K., Hoaas B.F., et al. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand J Immunol 41 (1995) 449-456
45. Li Y.Y., McTiernan C.F., and Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46 (2000) 214-224
46. Sivasubramanian N., Coker M.L., Kurrelmeyer K.M., et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104 (2001) 826-831
47. Shapiro S., Shoenfeld Y., Gilburd B., Sobel E., and Lahat N. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 95 (2002) 2032-2037
48. Senzaki H., Masutani S., Kobayashi J., et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 104 (2001) 860-863
49. Gurantz D., Yndestad A., Halvorsen B., et al. Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. Cardiovasc Res 67 (2005) 106-115
50. Ruiz de Souza V., Carreno M.P., Kaveri S.V., et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 25 (1995) 1267-1273
51. Muller F., Aukrust P., Nordoy I., and Froland S.S. Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Blood 92 (1998) 3721-3729
52. Aukrust P., Frøland S.S., Liabakk N.B., et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84 (1994) 2136-2143
53. Aukrust P., Muller F., Svenson M., et al. Administration of intravenous immunoglobulin (IVIG) in vivo down-regulatory effects on the IL-1 system. Clin Exp Immunol 115 (1999) 136-143
54. Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 19 (1999) 2847-2853
55. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 85 (1999) e17-e24
56. Nishio R., Matsumori A., Shioi T., Ishida H., and Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation 100 (1999) 1102-1108
57. Shito M., Wakabayashi G., Ueda M., et al. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. Transplantation 63 (1997) 143-148
58. Yang G.Y., Zhao Y.J., Davidson B.L., and Betz A.L. Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 751 (1997) 181-188
59. Suzuki K., Murtuza B., Smolenski R.T., et al. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 104 (2001) 308I-13